A comparative study of DIPEPTIDYL PEPTIDASE – 4 INHIBITOR WITH combination of SULFONYLUREAS and metformin

Neetu Devendra Singh[1], Miss Spardha Trehan[2]
[1]*Himalayan institute of pharmacy and research Rajawala Road*
[2]*Guide, Himalayan institute of pharmacy and research Rajawala Road*

Abstract- Background: Insulin resistance is a hallmark of type 2 diabetes mellitus (T2DM), a chronic metabolic disease. progressive beta-cell dysfunction, necessitating combination pharmacotherapy for optimal glycemic control. Metformin remains the first-line agent; however, inadequate control often requires addition of either Dipeptidyl Peptidase-4 (DPP-4) inhibitors or sulfonylureas. This study aimed to compare The effectiveness, security, and acceptability of Metformin combined with DPP-4 inhibitors versus Metformin combined with sulfonylureas in those with T2DM who are not successfully managed with metformin alone

INTRODUCTION

Diabetes Mellitus Type 2 (T2DM) Context

Insulin resistance and developing pancreatic β-mobile sickness are hallmarks of type 2 diabetes mellitus (T2DM), a chronic metabolic infection with more than one contributing element. If chronic hyperglycemia is not dealt with, it may bring about microvascular and macrovascular issues inclusive of stroke, retinopathy, nephropathy, neuropathy, and cardiovascular disorder. Type 2 diabetes is strongly related to genetic susceptibility and modifiable way of life factors, which includes horrific ingesting conduct, pressure, obesity, and bodily state of being inactive, in evaluation to kind 1 diabetes, that is basically autoimmune (DeFronzo et al., 2015).

Globally, the superiority of diabetes is shockingly developing. In 2021, 537 million human beings elderly 20 to 79 may additionally have diabetes, in step with the International Diabetes Federation. Since diabetes is predicted to have an effect on 643 million humans by way of 2030 and 783 million through 2045, it's miles one of the maximum urgent public health problems of the twenty-first century. Over ninety% of those times are as a result of type 2 diabetes.

MATERIALS AND METHODS

Four.1 Design of Research

This observe employed a randomized comparative medical trial layout to assess the protection and efficacy of commonly prescribed combination treatment plans in humans with Type 2 Diabetes Mellitus (T2DM). In particular, the studies in contrast Dipeptidyl Peptidase-four (DPP-4) inhibitors plus metformin with sulfonylureas plus metformin. The trial's ability format allowed for ongoing evaluation of the drug's outcomes over a six-month length. A computer-generated random sequence turn out to be utilized for randomization so you

Study Setting and Duration

The trial was finished within the Department of Pharmacology and Endocrinology, a education hospital that offers tertiary care and has sufficient room for scientific research and biochemical sorting out. Six months have been spent on study-up, six months on treatment, and 6 more months have been spent on player recruitment and baseline data amassing for the duration of the venture's 12-month length. Participants have been decided on from outpatient clinics and their eligibility became evaluated in accordance with scientific medical doctor tips. The purpose of the monthly take a look at-up conferences became to acquire blood samples, file bad activities, show medical development, and growth drug compliance.

Four.Three Criteria for Inclusion and Selection:

HbA1c tiers among 7. Five% and nine. Five% mean insufficient glycemic manage in humans aged 30 to sixty five who've been diagnosed with type 2 diabetes

(T2DM) based at the American Diabetes Association's (ADA) standards and who've been taking metformin monotherapy always for at least 3 months.

Requirements for Exclusion:
It is feasible to diagnose type 1 diabetes mellitus, gestational diabetes, and secondary diabetes due to other conditions.
The lifestyles of severe renal impairment (expected Glomerular Filtration Rate (eGFR) < 30 ml/min/1.73 m2), heart failure (NYHA class III or IV), or significant hepatic dysfunction (elevated transaminases >3 times better restrict).
Women who're nursing or pregnant due to capability teratogenicity or medication protection issues.
Use of insulin or another oral hypoglycemic drug, besides for metformin, within the preceding three months.
Participation in extra medical trials in some unspecified time in the future of the previous three months to keep away from confounding outcomes.

4.Four Sample Size and Grouping
Group A: Combination treatment collectively with metformin and a DPP-4 inhibitor (e.G., sitagliptin one hundred mg as soon as day by day).
Group B: Sulfonylurea and metformin combination treatment (glimepiride, for example, starting at 1 mg once every day and titrating as needed).

Four.Five Assessed Criteria
The check examined several additives to accurately determine the protection and efficacy of the mix remedy:

Glycemic Control:
To study the efficacy of remedy and lengthy-term glycemic manage, glycated hemoglobin, or HbA1c, is measured at baseline and three and 6 months later. The essential outcome is that HbA1c has a sturdy hyperlink with the results of diabetes.
The baseline and non-prevent glycemic recognition are monitored through monthly fasting blood sugar (FBS) measurements.
Glucose excursions following meals are evaluated via month-to-month postprandial blood sugar (PPBS) measurements.
Anthropometric and Renal Function Body weight is tracked every month to stumble on adjustments due to remedy because of the fact sulfonylureas are more likely to bring about weight advantage than DPP-4 inhibitors.
The urine albumin-to-creatinine ratio (UACR) is classified on the start and end of the look at to screen for microalbuminuria, a sign of diabetic nephropathy.
The systematic recording of destructive drug reactions (ADRs), together with gastrointestinal symptoms (nausea, diarrhea), hypoglycemia episodes (as indicated thru symptoms and signs and symptoms and blood glucose ranges), and each other aspect results, is part of protection and negative consequences.
A medical exam and important sign tracking are a part of each go to for you to find out any new or worsening scientific problems.

Four.6 Statistical Tools Utilized
All amassed facts modified into entered into the SPSS software program (version XX, which encompass SPSS 25.0) for statistical evaluation. The following strategies have been finished:
Means, famous deviations (SD), and probabilities are utilized in descriptive facts to summarize baseline demographic and clinical facts in addition to very last results factors.

Comparative Analysis: The paired t-take a look at became used to assess parameter changes from baseline to comply with-up elements for inner-organization comparisons.
O The unpaired t-take a look at or one-manner ANOVA had been used to evaluate non-prevent variables which includes weight, FBS, and HbA1c between Group A and Group B at numerous time intervals.
The chi-square test changed into used on particular statistics, much like the prevalence of hypoglycemic episodes and precise unfavorable effects, to evaluate versions in safety profiles amongst corporations.
When the p-price modified into much less than 0.05, the determined differences have been taken into consideration statistically big and had a much less than five% chance of being the stop end result of risk.

Data Visualization: Tables and graphs (bar charts, line graphs) have been made to truly show traits, remedy responses, and safety results

3- EXPERIMENTAL RESULTS

3.1 Baseline Characteristics

The baseline scientific and demographic traits of the study members for each companies are summarized in Table five 3.1. The absence of statistically substantial differences between Group A (Metformin + DPP-four inhibitor) and Group B (Metformin + Sulfonylurea) in phrases of age, gender distribution, length of diabetes, baseline HbA1c, fasting blood sugar (FBS), postprandial blood sugar (PPBS), frame weight, and renal parameters on the start of the examine demonstrated the two businesses' comparison.

Both companies—Group A (Metformin + DPP-4 inhibitor) and Group B (Metformin + Sulfonylurea)—have been nicely-matched earlier than treatment began out out, consistent with the baseline tendencies of check individuals displayed in Table five.1. With no statistically large difference (p = 0.Seventy six), the not unusual age of the two groups was similar (fifty .3 ± 7.Five years in Group A vs. Fifty one.Eight ± 8.1 years in Group B), indicating a balanced age distribution. Additionally, there has been no discernible gender-related bias, as indicated through the p-rate of zero.Seventy nine and the similar gender distribution (18 guys and 12 ladies in Group A; 17 character guys and 13 women in Group B). Group A and Group B tested comparable chronicity of Type 2 Diabetes Mellitus with propose periods of five.2 ± 2.1 and 5.Five ± 2.Four years, respectively (p = 0.Sixty three).

Furthermore, there was no change in frame composition that could have affected metabolic results because the baseline Body Mass Index (BMI) was almost the same for all cohorts (27.8 ± 3.2). According to the baseline characteristics of research participants shown in Table 4.1, both

Furthermore, due to the fact the baseline Body Mass Index (BMI) became nearly the same for all cohorts (27.Eight ± 3.2), there has been little change in frame composition that could have impacted metabolic outcomes. Both corporations—Group A (Metformin + DPP-4 inhibitor) and Group B (Metformin + Sulfonylurea)—had been properly-matched earlier than the initiation of treatment, primarily based on the baseline trends of research members displayed in Table 3.1With no statistically tremendous difference (p = zero.Seventy six), the average age of the 2 businesses have become similar (fifty two.Three ± 7.Five years in Group A vs. Fifty one.Eight ± eight.1 years in Group B), indicating a balanced age distribution. There turn out to be no discernible gender-related bias, as indicated via the p-fee of 0.Seventy nine and the comparable gender distribution (18 males and 12 girls in Group A; 17 males and thirteen girls in Group B). Group A and Group B tested similar chronicity of Type 2 Diabetes Mellitus with suggest periods of five.2 ± 2.1 and 5.Five ± 2.Four years, respectively (p = 0.63).



During the 6-month trial length, every remedy agencies' fasting blood sugar (FBS) degrees progressed statistically notably (Table 2.3).

In Group A (Metformin + DPP-4 inhibitor), the mean baseline FBS became 160.5 ± 20.Three mg/dL; however, it reduced to a hundred and forty.2 ± 18.6 mg/dL at 3 months after which to one hundred thirty.Five ± 15.2 mg/dL at 6 months. The waft, which represented an 18.7% lower, become statistically incredible (p < 0.001).

The FBS in Group B (Metformin + Sulfonylurea) reduced from a baseline of 162.7 ± 22.Five mg/dL to 138.7 ± 19.9 mg/dL at three months and to 128.Eight ± 14.7 mg/dL at 6 months, a 20.Nine% decrease that become similarly statistically wonderful (p < 0.001).

FBS emerge as correctly reduced by way of manner of every regimens, regardless of the fact that Group B's percent lower changed into marginally greater.



Over the direction of six months, postprandial blood sugar (PPBS) stages reduced statistically appreciably in both treatment groups, as confirmed in Table 4.4.

At three and six months, the mean baseline PPBS in Group A (Metformin + DPP-four inhibitor) dropped

from 230.7 ± 30.1 mg/dL to 2 hundred.Three ± 25.Four mg/dL and 185.6 ± 22.1 mg/dL, respectively. The beginning fee has reduced via 19.5%, and the drop is statistically awesome ($p < 0.001$).

The recommend PPBS for Group B (Metformin + Sulfonylurea) turned into 232.4 ± 28.7 mg/dL at baseline; it reduced with the useful resource of twenty-two.Four% to 195.8 ± 24.9 mg/dL and a hundred and 80.4 ± 21.Five mg/dL at 3 and 6 months, respectively, and have become statistically sizable ($p <$ zero.001).



In a function five. Five: Analysis of Body Weight Variations Throughout the Study

The effect of remedy on body weight all through a 6-month length in every businesses is established in Table 4.5. The findings show that the 2 remedy modes show off splendid developments:

The propose frame weight in Group A (Metformin + DPP-four inhibitor) dropped from 75.4 ± 9.2 kg at baseline to seventy four.3 ± eight.Nine kg after six months, a statistically giant ($p =$ zero.02) lack of 1.1 kg. This implies that DPP-four inhibitors, which are well known for their weight-neutral or slightly weight-lowering advantages, may be useful for T2DM patients.

Conclusion: Even if each regimens are effective for glycemic control, the DPP-four inhibitor combination is absolutely superior for weight balance or lower. Controlling weight is an critical a part of complete diabetes cope with human beings with type 2 diabetes who're obese or overweight. Sulfonylureas' propensity to reason weight gain can also restriction their prolonged-term use, specifically in folks who are greater prone to the harmful results of weight troubles.





Interpretation: Over the path of six months, the PPBS ranges in both organizations decreased dramatically and regularly.

Because sulfonylureas have an instantaneous insulinotropic effect, Group B (sulfonylurea) showed a little quicker reduction, mainly within the first 3 months.

Given their feature in glucose-structured insulin launch and more stable glycemic control, Group A (DPP-4 inhibitors) indicates a extra sluggish and steady drop.

Groups A and B every finished 185.6 and one hundred eighty. Four mg/dL thru the prevent of six months, respectively, demonstrating successful postprandial glycemic manipulate.

There is a significant version in the safety profiles of the 2 remedy regimens primarily based at the frequency of side consequences experienced by way of research individuals. Group A (Metformin + DPP-four inhibitor) became impacted by hypoglycemic activities in first-rate 2 individuals (6.7%), with a statistically first rate p-fee of 0.04 and 7 out of 30 individuals (23.Three%). In evaluation, Group B (Metformin + Sulfonylurea) professional hypoglycemic episodes extensively greater often. This confirms previous research at the improved threat of hypoglycemia related to sulfonylureas.

Group B said 10.Zero% gastrointestinal issues, whereas Group A stated fantastically more (16.7%), however the difference become now not statistically

tremendous (p = zero.44), suggesting that each drug treatments were generally properly-tolerated in this regard.

In each companies, vertigo and allergic responses have been unusual and came about at low, statistically insignificant prices. While there has been best one rash occasion inside the sulfonylurea institution, dizziness have become stated by way of one player in Group A and in Group B (p = zero.31 and 0.Fifty five, respectively).

These consequences display that DPP-4 inhibitors are more secure and extra tolerable while used with metformin, specifically on the subject of decreasing hypoglycemia and weight-related issues.



The FTIR spectrum of sitagliptin, a DPP-4 inhibitor, indicates numerous characteristic peaks that correspond to massive beneficial agencies within the molecule. A superb absorption top located at 3300 cm^{-1}, which is suggestive of N–H stretching vibrations, confirms the presence of an amine group, that is required for the drug's binding affinity and hydrogen bonding interactions with the DPP-4 enzyme. The presence of hydrocarbon chains supporting the molecule's spine shape is confirmed via a medium intensity top at 2950 cm^{-1}, which represents the C–H stretching of aliphatic alkane organizations.



Two separate peaks at wavelengths of 248 nm and 312 nm can be seen within the sitagliptin in methanol UV–Vis absorption spectra. A π → π* transition, this is normally associated with the presence of conjugated aromatic ring organizations, is proven thru the sizeable absorption at 248 nm. This indicates that sitagliptin's wonderful UV absorbance is due to the presence of aromatic moieties that have the ability to delocalize electrons. A n → π* transition is answerable for the second top, that's fairly robust at 312 nm. These transitions, which typically arise even as non-bonding electrons (lone pairs) on heteroatoms like nitrogen or oxygen interact with π* orbitals, endorse the presence of lone-pair-bearing atoms or practical corporations like carbonyls within the chemical shape. All of those absorption traits aid the interplay of Sitagliptin with UV light via digital excitation strategies and validate vital structural components

SUMMARY, CONCLUSION, AND FUTURE SCOPE

Results Synopsis

The current observe protected individual sufferers taking metformin monotherapy who had insufficient glycemic manage over a six-month length to assess the safety and effectiveness of popular aggregate treatments for Type 2 Diabetes Mellitus: metformin plus DPP-4 inhibitors toward metformin plus sulfonylureas. The effectiveness of twin treatment in enhancing glucose control have become confirmed by using the statistically large enhancements in key glycemic markers that each treatment companies showed, inclusive of decreases in HbA1c, fasting blood sugar (FBS), and postprandial blood sugar (PPBS) degrees.

Overall, the effects emphasize the significance of safety and efficacy whilst selecting antidiabetic regimens, showing that no matter the fact that sulfonylureas are appropriate at reducing blood sugar, their prolonged-term use may be restrained because of the risk of weight gain and hypoglycemia. On the opportunity hand, DPP-four inhibitors are a brilliant desire for customized diabetes remedy while used with metformin due to the truth they provide a well-rounded profile, prolonged-lasting glycemic upgrades, and much less unfavorable outcomes.5.2 Conclusion

The effects of this randomized comparative look at suggest that every combination remedies—metformin with sulfonylureas and metformin with Dipeptidyl Peptidase-four (DPP-four) inhibitors—can assist sufferers with Type 2 Diabetes Mellitus (T2DM) who aren't accurately controlled on metformin

monotherapy. Each habitual's recuperation success in medical exercising was proven by the massive decreases in important glycemic indicators such HbA1c, fasting blood sugar (FBS), and postprandial blood sugar (PPBS) all through the direction of the six-month trial duration.

However, in terms of protection, tolerance, and prolonged-time period manipulate issues, the mixture of metformin and DPP-four inhibitors modified into truly higher while the total advantage-risk profile have become considered. Due to their strong insulin secretagogue motion, sulfonylureas showed a quicker preliminary drop in blood glucose stages; despite the fact that, this have become accompanied by using way of a extensively better frequency of component effects, which includes clinically top notch weight gain and symptomatic hypoglycemia. In addition to endangering patient protection, the ones side outcomes pose essential limitations to lengthy-term metabolic control and adherence, particularly in prone businesses much like the elderly, human beings with underlying cardiovascular or renal situations, and those with strange consuming styles

REFERENCE

[1] Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13(1):7-18.

[2] Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.

[3] Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360-372.

[4] Nathan DM. Management of hyperglycemia in type 2 diabetes: a consensus algorithm. Diabetes Care. 2009;32(1):193-203.

[5] Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2012;38(2):89-101.

[6] Bailey CJ, Day C. Sulfonylureas and metformin: a comparative review. Diabetes Res Clin Pract. 2004;65(Suppl 1):S3-S7.

[7] Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589.

[8] Gerich JE. Role of the kidney in normal glucose homeostasis and in diabetes mellitus. Diabetes Care. 2010;33(10):235-241.

[9] Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.

[10] Schweizer A, et al. Pharmacokinetics and pharmacodynamics of DPP-4 inhibitors. Clin Pharmacokinet. 2008;47(6):383-402.

[11] Chacra AR, et al. Sitagliptin compared with glipizide in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized trial. Diabetes Care. 2007;30(6):1460-1466.

[12] Yki-Järvinen H. Combination therapy in type 2 diabetes: Sulfonylureas and Metformin. Diabetes Obes Metab. 2004;6(6):345-353.

[13] Pratley RE, et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes. Diabetes Care. 2007;30(12):1639-1643.

[14] Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.

[15] Rosenstock J, et al. Efficacy and safety of sitagliptin added to metformin. Diabetes Obes Metab. 2006;8(5):408-417.

[16] Fonseca V, et al. Safety and efficacy of vildagliptin added to metformin. Diabetes Care. 2007;30(6):1237-1243.

[17] Nauck MA, et al. Efficacy and safety of linagliptin monotherapy. Diabetes Obes Metab. 2011;13(7):595-604.

[18] Charbonnel B, et al. Efficacy and safety of saxagliptin as monotherapy. Diabetes Care. 2009;32(8):1484-1490.

[19] Wang J, et al. Meta-analysis of DPP-4 inhibitors versus sulfonylureas. Diabetes Res Clin Pract. 2014;106(1):63-73.

[20] American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1-S268.

[21] Turner RC, et al. UKPDS 33: Intensive blood-glucose control with sulfonylureas or insulin. Lancet. 1998;352(9131):837-853.

[22] Henry RR, et al. DPP-4 inhibitors and risk of hypoglycemia. Diabetes Care. 2007;30(12):3180-3182.

[23] Campbell RK. Sulfonylurea class adverse effects and contraindications. J Diabetes. 2011;3(3):147-150.

[24] Monami M, et al. DPP-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(3):224-231.
[25] Bosi E. Treatment of type 2 diabetes: new agents and strategies. Eur J Intern Med. 2009;20(4):299-309.
[26] Polonsky WH, et al. Metformin: a review of its pharmacology and clinical efficacy. Diabetes Educ. 1996;22(6):574-581.
[27] Vora J, et al. Safety of sulfonylureas: hypoglycemia and weight gain. J Diabetes Metab Disord. 2016;15:42.
[28] Seino Y, et al. The mechanisms of action of incretin-based therapies. J Diabetes Investig. 2010;1(3):104-111.
[29] Pratley RE, et al. Efficacy and safety of DPP-4 inhibitors compared with sulfonylureas. Diabetes Obes Metab. 2014;16(2):113-120.
[30] Bailey CJ. Metformin: its pharmacological properties and clinical use. Diabetes Vasc Dis Res. 2017;14(3):173-178.
[31] Hong J, et al. Combination therapy with metformin and sulfonylureas in diabetes. Diabet Med. 2004;21(5):418-425.
[32] Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes. Diabetes Care. 2012;35(6):1364-1379.
[33] DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303.
[34] Buse JB, et al. Effect of sitagliptin on glycemic control: a meta-analysis. Diabetes Care. 2007;30(6):1481-1486.
[35] Matthews DR, et al. Sulfonylureas and risk of hypoglycemia. Diabetes Care. 2003;26(4):1032-1037.
[36] Gantz I, et al. The pharmacodynamics of metformin and sulfonylurea. Endocr Rev. 2014;35(3):245-271.
[37] Weir MR. The safety of DPP-4 inhibitors. J Clin Hypertens (Greenwich). 2012;14(8):562-567.
[38] Davies MJ, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2018;41(12):2669-2701.
[39] Amori RE, et al. Efficacy and safety of incretin-based therapies. JAMA. 2007;298(2):194-206.
[40] Henry RR, et al. Cardiovascular outcomes of DPP-4 inhibitors. Diabetes Care. 2013;36(11):3869-3876.
[41] Abdul-Ghani MA, et al. Metformin and sulfonylureas: mechanisms and efficacy. Endocr Pract. 2007;13(4):401-410.
[42] Fadini GP, et al. Meta-analysis on cardiovascular safety of DPP-4 inhibitors. Diabetes Obes Metab. 2015;17(7):676-683.
[43] Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-579.
[44] Kirpichnikov D, et al. Metformin: an update. Diabetes Care. 2002;25(6):1113-1119.
[45] Scheen AJ. Pharmacokinetics of sulfonylureas. Clin Pharmacokinet. 1996;31(6):441-463.
[46] Fonseca VA. Clinical considerations for sulfonylurea therapy. Diabetes Care. 1997;20(5):695-700.
[47] Lavalle-González FJ, et al. Efficacy and safety of DPP-4 inhibitors: a systematic review. Diabetes Ther. 2013;4(2):175-194.
[48] Scirica BM, et al. Cardiovascular safety of saxagliptin. N Engl J Med. 2013;369(14):1317-1326.
[49] Bethel MA, et al. Cardiovascular safety of DPP-4 inhibitors. Diab Vasc Dis Res. 2018;15(2):112-120.
[50] He YL, et al. DPP-4 inhibitors: a review of efficacy and safety. Int J Clin Pharmacol Ther. 2014;52(8):608-617.
[51] Green JB, et al. Effect of sitagliptin on cardiovascular outcomes. N Engl J Med. 2015;373(3):232-242.
[52] Vilsbøll T, et al. DPP-4 inhibitors and weight neutrality. Diabetes Obes Metab. 2012;14(10):903-911.
[53] Hsia D, et al. Metformin and cardiovascular disease. Diabetes Care. 2012;35(4):956-965.
[54] Hanefeld M, et al. Safety and efficacy of glimepiride vs. other sulfonylureas. Diabetes Obes Metab. 2013;15(7):658-666.
[55] Hermansen K, et al. Vildagliptin efficacy and safety in type 2 diabetes. Diabetes Obes Metab. 2007;9(5):647-659.
[56] Henry RR, et al. Sitagliptin safety and efficacy in patients with renal impairment. Diabetes Care. 2009;32(4):632-637.

[57] Monami M, et al. Safety of DPP-4 inhibitors: a meta-analysis. Diabetes Obes Metab. 2011;13(3):183-190.
[58] Nauck MA, et al. DPP-4 inhibitors and pancreatic safety. Diabetes Care. 2017;40(2):261-265.
[59] Leiter LA, et al. Cardiovascular safety of DPP-4 inhibitors. Diabetes Care. 2016;39(11):2064-2071.
[60] Kuhadiya ND, et al. Effect of sulfonylureas on cardiovascular risk factors. Curr Med Res Opin. 2016;32(7):1175-1183.
[61] Del Prato S, et al. Long-term efficacy of DPP-4 inhibitors. Diabetes Care. 2012;35(5):969-975.
[62] Madsbad S, et al. Efficacy of DPP-4 inhibitors in type 2 diabetes. Diabetes Obes Metab. 2011;13(4):327-335.
[63] McIntosh CH, et al. Mechanisms of action of incretin-based therapies. Diabetes Care. 2009;32(2):218-226.